alectinib (Alecensa)
Jump to navigation
Jump to search
Indications
- ALK*+ non-small cell lung cancer (NSCLC) in patients who fail crizotinib[1]
- alectinib superior to crizotinib with lower toxicity in untreated ALK*+ NSCLC[2]
- may benefit patients with brain metastases[1]
* ALK = anaplastic lymphoma kinase
Contraindications
Dosage
Capsule: 150 mg
Adverse effects
- most cammon
- fatigue (41%), constipation (34%), edema (30%),
- myalgia (29%) with increased serum creatine kinase
- other
- hepatoxicity, increased serum transaminases
- interstitial lung disease
- bradycardia
- photosensitivity
Mechanism of action
- inhibits anaplastic lymphoma kinase
More general terms
References
- ↑ 1.0 1.1 1.2 FDA News Release. December 11, 2015 FDA approves new oral therapy to treat ALK-positive lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
- ↑ 2.0 2.1 Peters S, Camidge DR, Shaw AT et al Alectinib versus Crizotinib in Untreated ALK-Positive Non- Small-Cell Lung Cancer. N Engl J Med 2017; 377:829-838. August 31, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28586279 Free full text <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1704795
- ↑ Prescribing Information: https://www.alecensa.com/hcp.html